Dutch biotechnology firm Pharming has developed a treatment for hereditary angioedema, called Rhucin, that is derived from milk collected from rabbits genetically modified to produce C1 inhibitor. The company plans to collect the rabbit milk on a mass scale using mini-pumping machines, providing Rhucin is approved by European regulators.

Full Story:

Related Summaries